Bayer Bolsters Nucleic Acid Diagnostics Portfolio With VGI Acquisition
This article was originally published in The Gray Sheet
Executive Summary
Bayer Diagnostics will gain the only FDA-approved HIV sequencing resistance test available in the U.S. through its roughly $60 mil. cash acquisition of Visible Genetics, Inc